Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Accured Expenses (2021 - 2025)

Verrica Pharmaceuticals has reported Change in Accured Expenses over the past 5 years, most recently at -$400000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$400000.0 for Q4 2025, up 92.28% from a year ago — trailing twelve months through Dec 2025 was -$1.3 million (down 345.92% YoY), and the annual figure for FY2025 was -$1.3 million, down 345.92%.
  • Change in Accured Expenses for Q4 2025 was -$400000.0 at Verrica Pharmaceuticals, up from -$501000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for VRCA hit a ceiling of $5.5 million in Q3 2023 and a floor of -$5.2 million in Q4 2024.
  • Median Change in Accured Expenses over the past 5 years was $496500.0 (2021), compared with a mean of $481950.0.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 581.82% in 2022 and later surged 7011.11% in 2023.
  • Verrica Pharmaceuticals' Change in Accured Expenses stood at -$700000.0 in 2021, then surged by 110.29% to $72000.0 in 2022, then surged by 7011.11% to $5.1 million in 2023, then crashed by 201.17% to -$5.2 million in 2024, then skyrocketed by 92.28% to -$400000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$400000.0 (Q4 2025), -$501000.0 (Q3 2025), and -$1.4 million (Q2 2025) per Business Quant data.